Johnson & Johnson’s $3.5 Billion Prostate Cancer Drug Sales At Risk?

+7.03%
Upside
182
Market
195
Trefis
JNJ: Johnson & Johnson logo
JNJ
Johnson & Johnson

Johnson & Johnson (NYSE:JNJ) is the leader in the prostate cancer hormonal therapy market, with Zytiga sales of $3.5 billion in 2018. Other key drugs include Astellas’ Xtandi, and AbbVie’s Lupron. However, Zytiga could see a sharp decline in sales over the next few years, as it will face biosimilar competition. The U.S. Court of Appeals for the Federal Circuit rejected a request by Johnson & Johnson for a temporary restraining order blocking sales of generic versions of Zytiga in November 2018. While AbbVie’s Lupron could also see an end of market exclusivity period in 2019, Astellas’ Xtandi is protected till 2027. In this note we compare Zytiga with other prostate cancer drugs. You can view our interactive dashboard analysis ~ Are Johnson & Johnson’s $3.5 Billion Prostate Cancer Drug Sales At Risk? ~ for more details.  In addition, you can see more of our data for Healthcare companies here.

Johnson & Johnson’s Zytiga Is The Top Selling Prostate Cancer Drug, Followed By Astellas’ Xtandi

  • 2018 Sales:
    • Zytiga (J&J): $3.5 Billion
    • Xtandi (Astellas): $2.7 Billion
    • Lupron (AbbVie): $892 Million
    • Zoladex (AstraZeneca): $752 Million
    • Jevtana (Sanofi): $498 Million
    • Xofigo (Bayer): $415 Million
    • Taxotere (Sanofi): $196 Million
Relevant Articles
  1. Here’s Why Centene Stock Is A Better Bet Compared To This Pharmaceuticals Bellwether
  2. This Semiconductor Chip Company Is Likely To Offer Better Returns Over Johnson & Johnson Stock
  3. Does Johnson & Johnson Stock Have More Upside?
  4. Company Of The Day: Johnson & Johnson
  5. Here’s Why Humira Maker Is A Better Bet Compared To Johnson & Johnson Stock
  6. Despite Its Mixed Q4 Johnson & Johnson Stock May See Higher Levels

Zytiga’s Share In Prostate Cancer Drugs Market Is Declining

  • Combined sales of prostate cancer drugs above grew from $5.5 billion in 2014 to $8.9 billion in 2018.
  • Zytiga’s share declined slightly from 40% to 39% during the same period, and it could decline to 25% over the next few years, as it could see its sales decline amid patent expiry.
  • Zytiga is facing generic competition in 2019. Xtandi’s market exclusivity period ends in 2027 while that of Lupron will end in 2019.
  • Given the generic competition, Zytiga’s global sales in Q2 2019 declined 20%, while the U.S. sales plummeted 59%.

Zytiga Is Relatively A Small Drug For Johnson & Johnson, And It Accounts For Only 9% of The Company’s Total Pharmaceutical Sales

What’s behind Trefis? See How it’s Powering New Collaboration and What-Ifs

For CFOs and Finance Teams | Product, R&D, and Marketing Teams

All Trefis Data

Like our charts? Explore example interactive dashboards and create your own.